{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F5ac6484c-2e3e-415c-88e6-e9d402832f32","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Bispecific Antibodies in the Management of Multiple Myeloma\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/5ac6484c-2e3e-415c-88e6-e9d402832f32\"></iframe>","title":"Bispecific Antibodies in the Management of Multiple Myeloma","description":"\n        <p>Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.</p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayBispecificMM24\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/848a79ae-433f-49bf-8abf-d8ee2f3cd91c/cover.jpg"}